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 Non-alcoholic fatty liver disease (NAFLD) and heart
disease share risk factors.
 Serum remnant lipoprotein cholesterol (RLP-C) is
linked with severity of liver fat.
 Males with NAFLD have higher cardiometabolic
risk.
 RLP-C may contribute to risk of cardiovascular
disease in people with NAFLD.
Lay summary
Remnant lipoprotein cholesterol (RLP-C) is a part of
the blood cholesterol that is linked with heart disease
and non-alcoholic fatty liver disease (NAFLD) in adults.
In the Raine Study, teenagers with high RLP-C levels
had more severe fat accumulation in their liver. Thus,
RLP-C might be the hidden link between NAFLD and
future risk of heart disease.
https://doi.org/10.1016/j.jhepr.2020.100150
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Background & Aims: Remnant lipoprotein cholesterol (RLP-C) is an atherogenic lipid profile associated with non-alcoholic
fatty liver disease (NAFLD) and cardiovascular disease (CVD). With increased rates of CVD seen in adults with NAFLD,
RLP-C has the potential to identify individuals with NAFLD who are at increased risk of CVD. This study examined in
adolescents sex-different associations among RLP-C, NAFLD, and cardiometabolic risk factors, and whether RLP-C is associated
with NAFLD beyond traditional cardiometabolic risk factors.
Methods: Adolescents in the Raine Study had anthropometry, clinical, biochemistry and arterial stiffness measurements
recorded at 17 years of age. Fatty liver, subcutaneous and visceral adipose thickness were assessed using abdominal ultra-
sound. Relationships among RLP-C, NAFLD, liver biochemistry, insulin resistance, adipokines, adiposity and arterial stiffness
were assessed.
Results: NAFLD was diagnosed in 15.1% (19.6% females and 10.7% males) of adolescents. Increasing RLP-C levels were asso-
ciated with increasing severity of hepatic steatosis and metabolic syndrome. Adolescents with NAFLD and serum RLP-C levels
in the highest quartile compared with the lowest quartile, had higher serum leptin, homeostatic model assessment of insulin
resistance (HOMA-IR), high-sensitivity C-reactive protein, low-density-lipoprotein cholesterol, triglycerides, BMI, subcu-
taneous and visceral adipose thickness, systolic blood pressure and arterial stiffness, but lower adiponectin and high-density-
lipoprotein cholesterol. Using multivariable logistic regression, RLP-C in the lowest quartile compared with the highest
quartile was associated with 85% lower odds of NAFLD in males and 55% in females, after adjusting for waist circumference,
leptin, ALT, adiponectin and HOMA-IR.
Conclusions: There is an association between RLP-C and NAFLD beyond traditional risk factors of adiposity and insulin
resistance in adolescents. Although raised serum RLP-C levels were associated with the severity of hepatic steatosis and
markers of cardiometabolic risk, lower serum RLP-C might reflect reduced cardiovascular risk.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver dis-
order typified by accumulation of fat in the liver, with variable
degrees of inflammation or hepatic fibrosis, in the absence of
excessive alcohol.1 It is associated with the metabolic syndrome,
primarily abdominal obesity, hypertriglyceridaemia, type 2 dia-
betes mellitus (T2DM) or fasting glycaemia and low levels of
serum high-density cholesterol (HDL-C).2,3 It is the most com-
mon cause of chronic liver disease globally, with population
estimates ranging from 13.5% to 31.8% depending on theKeywords: Metabolic syndrome; NAFLD; Cardiometabolic risk; Lipids; Adiposity;
Arterial stiffness; Raine study.
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population increases with the number of features of the meta-
bolic syndrome and with age.2–6 Previous studies reported
population prevalence ranges of 3–18% in adolescents and a
global prevalence of up to 25% in adults, increasing to >90% in
very obese adults and 38% in obese children.5–11 Sex differences
in the prevalence and phenotype of NAFLD associated with
adiposity distribution have also been reported.5
The global burden of NAFLD has progressively increased over
recent decades, likely as a result of an increased prevalence of
obesity, T2DM, dyslipidaemia and hypertension, which are con-
current risk factors for cardiovascular disease (CVD). CVD is the
leading cause of disease burden in adults globally.4,12,13 Adults
with NAFLD have a 2-fold increased risk of coronary artery dis-
ease and have increased cardiovascular events.14 Individuals
with NAFLD also have a lipid profile referred to as the ‘athero-
genic lipid triad’, typified by increased levels of low-density
lipoprotein cholesterol (LDL-C) and triglycerides (TG), and low
HDL-C.15 A longitudinal community follow-up study in the USA
Research articleshowed an increasing incidence of NAFLD, particularly in ado-
lescents and young adults, and an association between NAFLD
and increased cardiovascular events over 10 years.16
Remnant lipoprotein cholesterol (RLP-C), the cholesterol
contained in very-low-density lipoprotein (VLDL), was associated
with incident coronary heart disease in adults in the Jackson
Heart and Framingham Offspring Cohort Studies in the USA.17
More recently, NAFLD was independently associated with
higher circulating RLP-C levels that were linked with a higher
risk of major adverse cardiovascular and cerebrovascular events
in outpatients with NAFLD and features of the metabolic
syndrome or atrial fibrillation from Italian hospitals.18 Car-
diometabolic risk factors, such as abdominal obesity, dyslipi-
daemia and hyperinsulinism, have been associated with NAFLD
in Raine Study participants aged 17 years.5 Adolescents with
NAFLD and increased waist circumference, triglycerides, insulin,
systolic blood pressure, but lower HDL-C, also had higher arterial
stiffness.19 RLP-C was also recently associated with NAFLD and
raised liver transaminases in 17-year-old adolescents from the
Avon Longitudinal Study of Parents and Children in the UK.20
As the prevalence of NAFLD continues to rise, knowledge of
preclinical cardiometabolic risk factors in young people with
NAFLD, using noninvasive assessments, may identify opportu-
nities to ameliorate future cardiovascular risk burden. The pri-
mary aim of our study was to examine sex-based associations
between RLP-C, NAFLD and a range of cardiometabolic risk
factors, including adiposity, homeostatic model assessment of
insulin resistance (HOMA-IR), serum alanine transferase (ALT),
adipokines and measures of arterial stiffness, in 17-year-old ad-
olescents. The secondary aim was to determine whether RLP-C
was associated with NAFLD beyond traditional risk factors of
adiposity and insulin resistance in adolescents.Methods
Study population
The Raine Study was established as a pregnancy cohort exam-
ining the impact of repeated antenatal ultrasound examinations
on foetal outcomes. The cohort comprised 2,900 predominantly
Caucasian women (generation 1 or Gen1) between 16 and 18
weeks’ gestation, recruited from the general outpatient antenatal
clinic at King Edward Memorial Hospital (Subiaco, WA, Australia)
and nearby private practices between 1989 and 1991. The
women gave birth to 2,868 live neonates (generation 2 or Gen2),
who have since been followed up at 1–3-year intervals.21 A 17-
year cross-sectional assessment of the cohort was conducted
between 2006 and 2009, during which 1,726 Gen2 adolescents
were followed up. During this assessment, the Raine Study
families were considered representative of the broader Western
Australian population.22 Using charts with pictures and de-
scriptions of the Tanner pubertal stages, the adolescents
matched their individual pubertal appearance with the appro-
priate stage, as previously reported.5 Assessments included a
detailed health and lifestyle questionnaire, anthropometric and
cardiovascular assessments, fasting bloods and an abdominal
ultrasound. Institutional ethics committee approval was ob-
tained from the Princess Margaret Hospital for Children Human
Research Ethics Committee. Parents or legal guardians provided
signed informed consent and the adolescent provided personal
assent for participation in the study.JHEP Reports 2020Abdominal ultrasound assessment
Details of the ultrasound protocol for assessing fatty liver (he-
patic steatosis) and abdominal fat compartments have been
previously reported.5 Trained ultrasonographers conducted the
ultrasound examinations and a single specialist radiologist
interpreted the resulting images. The ultrasonographers and
radiologist were blinded to the clinical and laboratory charac-
teristics of the study participants. The presence or absence of
hepatic steatosis was based on scoring of echotexture, deep
attenuation and vessel blurring, using scores of 0–3, 0–2 and 0–1,
respectively. The diagnosis of fatty liver (hepatic steatosis)
required a total score of at least 2, comprising an echotexture
score of at least 1. The severity of hepatic steatosis was cat-
egorised by the total fatty liver score as 0–1 (no fatty liver), 2–3
(mild fatty liver) and 4–6 (moderate–severe fatty liver). The
intraobserver reliability (K statistic) for reporting hepatic stea-
tosis was 0.78 (95% CI 0.73–0.88). Visceral adipose tissue thick-
ness (VAT) was measured as the distance between the anterior
wall of the aorta and the internal face of the rectus abdominis
muscle perpendicular to the aorta. Subcutaneous adipose tissue
thickness (SAT) was measured as the thickness of the fat tissue
between the skin–fat interface and the linea alba, avoiding SAT
compression. The intraclass correlation coefficient was 0.93 for
SAT (95% CI 0.93–0.93) and 0.94 for VAT (95% CI 0.94–0.95).Definition of NAFLD
NAFLD was diagnosed if hepatic steatosis was detected using
liver ultrasound, in the absence of excessive alcohol intake and
without identifiable secondary causes. Adolescents with a self-
reported alcohol intake threshold of <140 g per week for fe-
males and 210 g per week in males, consistent with recent
NAFLD diagnosis and management guidelines, were classified as
having NAFLD. Testing for viral serology for HBV or HCV was not
carried out, given the notification rates for HBV and HCV in-
fections were, on average, <24/100,000 and <23/100,000,
respectively, for Western Australian teenagers between the ages
of 15 and 19 years over the study period.2,5Arterial stiffness assessment
Assessment of arterial stiffness was performed using a Sphyg-
moCor Pulse Wave System as previously described.19 Blood
pressure was measured by oscillometric sphygmomanometer
(DINAMAP vital signs monitor 8100, DINAMAP XL vital signs
monitor or DINAMAP ProCare 100). The Pulse Wave Analysis
System (SCOR-Px) and SphygmoCor Pulse Wave System (SCOR-
Vx) were used. Tonometers were applied to two sites (the carotid
artery and distal dorsalis pedis). Pulse wave analysis was
collected from the radial artery with the wrist facing upwards.
Pulse wave velocity (PWV) was calculated dividing the distance
between tonometers by the transit time of the arterial pulse
wave. An Aortic Augmentation Index (AIx) was defined as the
difference in the second and first systolic pressure peaks as a
percentage of pulse pressure. AIx measures the central arterial
reflected pressure wave occurring after distension of peripheral
vessels with systole. Reduced elasticity of peripheral arterial
vessels is reflected by the pressure wave occurring earlier
after cardiac ejection, augmenting systolic pressure. Central
Augmentation Pressure/Pulse Height Ratio at Heart Rate 75
(C-AGPH-HR75) was calculated to represent an arterial stiffness
measure adjusting PWV and AIx for a heart rate of 75.2vol. 2 j 100150
Table 1. Cohort characteristics.
Characteristic Males Female
NAFLD (n = 63) No NAFLD (n = 528) p value NAFLD (n = 113) No NAFLD (n = 463) p value
Anthropometry
Weight (kg) 94.5 ± 20.4 69.4 ± 11.0 <0.001 72.9 ± 17.2 60.9 ± 10.0 <0.001
BMI (kg/m2) 29.3 ± 5.9 21.9 ± 3.1 <0.001 26.3 ± 5.9 22.2 ± 3.4 <0.001
Waist circumference (cm) 98.1 ± 15.6 78.3 ± 7.7 <0.001 85.3 ± 14.6 75.5 ± 9.3 <0.001
Abdominal obesity (%) 59.0 4.2 <0.001 61.5 25.7 <0.001
Suprailiac SFT (mm) 26.2 ± 11.0 11.4 ± 7.0 <0.001 24.0 ± 9.1 17.0 ± 6.7 <0.001
SAT (mm) 31.4 ± 14.2 12.5 ± 7.7 <0.001 30.0 ± 14.7 18.6 ± 6.6 <0.001
VAT (mm) 41.6 ± 16.4 34.7 ± 9.9 <0.001 31.4 ± 9.8 29.5 ± 8.7 0.09
Cardiovascular
SBP (mmHg) 124.3 ± 9.8 119.3 ± 10.2 <0.001 110.4 ± 9.3 109.3 ± 9.6 0.29
DBP (mmHg) 60.2 ± 7.1 59.2 ± 6.6 0.29 59.8 ± 6.0 59.6 ± 6.6 0.83
Pulse per minute 66.7 ± 12.1 62.5 ± 10.2 0.003 67.5 ± 9.6 66.8 ± 9.9 0.46
Biochemistry
ALT (U/L) 39.1 ± 23.6 22.1 ± 9.9 <0.001 19.7 ± 13.3 18.1 ± 10.2 0.20
AST (U/L) 31.4. ± 14.5 27.0 ± 8.3 0.001 21.3 ± 5.4 22.0 ± 5.1 0.19
GGT (U/L) 23.7 ± 14.1 15.4 ± 7.3 <0.001 13.9 ± 6.8 13.0 ± 6.8 0.24
Glucose (mmol/L) 5.0 ± 0.5 4.8 ± 0.7 0.08 4.6 ± 0.4 4.7 ± 0.4 0.70
Total cholesterol (mmol/L) 4.0 ± 0.9 3.9 ± 0.7 0.34 4.4 ± 0.9 4.3 ± 0.7 0.41
HDL-C (mmol/L) 1.1 ± 0.2 1.2 ± 0.2 <0.001 1.3 ± 0.3 1.4 ± 0.3 0.001
LDL-C (mmol/L) 2.4 ± 0.8 2.2 ± 0.6 0.16 2.5 ± 0.7 2.4 ± 0.6 0.13
Triglycerides (mmol/L) 1.3 ± 0.6 1.0 ± 0.6 <0.001 1.1 ± 0.6 1.0 ± 0.5 0.01
RLP-C (mmol/L) 0.6 ± 0.3 0.5 ± 0.3 0.007 0.5 ± 0.3 0.5 ± 0.1 0.006
Leptin (lg/L) 12.8 (6.2–28.4) 2.3 (1.4–5.2) <0.001 43.3 (27.1–66.4) 22.4 (13.9–35.8) <0.001
Adiponectin (mg/L) 6.6 ± 2.8 8.4 ± 5.2 0.01 9.3 ± 4.6 11.9 ± 6.4 <0.001
hsCRP (mg/L) 1.2 (0.6–2.5) 0.4 (0.2–0.8) <0.001 1.3 (0.4–4.6) 0.7 (0.3–1.8) 0.001
Fasting insulin (mU/L) 10.5 (6.6–19.4) 6.8 (4.4–9.8) <0.001 9.7 (6.8–15.6) 7.5 (5.1–10.7) <0.001
HOMA-IR 2.3 (1.4–4.1) 1.4 (0.9–2.1) <0.001 2.1 (1.3–3.1) 1.5 (1.0–2.2) <0.001
Metabolic syndrome (%) 21.8% 1.6% <0.001 9.9 1.7% 0.001
Arterial stiffness measurements
C-AGPH-HR75 −3.3 (−14.8 to 3.5) −10.5 (−18.3 to −3.0) <0.001 −6.3 (−12.3 to 0.0) −6.5 (−13.5 to 1.0) 0.66
Arterial augmentation index 105.0 (93.5–110.4) 97.0 (89.50–105.5) 0.002 98.5 (91.5–106.1) 99.0 (92.4–107.5) 0.93
Arterial pulse wave velocity 6.6 (6.2–7.2) 6.6 (6.2–7.1) 0.48 6.3 (5.9–6.7) 6.3 (5.8–6.7) 0.59
Data are presented as mean ± standard deviation, median (interquartile range) or as proportions. Differences in continuous variables between adolescents with or without
NAFLD were computed using the independent t test or the Mann-Whitney U test. Differences between categorical variables were determined with the Pearson Chi-square test
or Fisher's exact test. p values are for associations between RLP-C and other variables. p values <0.05 are considered statistically significant.
Metabolic syndrome is defined using International Diabetes Federation (IDF) criteria. Abdominal obesity was defined as waist circumference >−80 cm in females and >−94 cm in
males.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; C-AGPH-HR75, Central Augmentation Pressure/Pulse Height Ratio at Heart Rate 75; DBP, diastolic blood
pressure; GGT, gamma-glutamyl transpeptidase; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin resistance; hsCRP, high
sensitivity CRP; LDL-C, low density lipoprotein cholesterol; RLP-C, remnant lipoprotein cholesterol; SAT, subcutaneous adipose thickness; SBP, systolic blood pressure; SST,
suprailiac skinfold thickness; VAT, visceral adipose thickness.Anthropometry
Body weight was measured in kilograms (kg) using a Wedder-
burn Chair Scale (to the nearest 100 g), height in cm with a
Holtain Stadiometer (to the nearest 0.1 cm) with participants
dressed in light clothes without shoes, and waist circumference
(cm) at the umbilicus level with a tape measure (to the nearest
0.1 cm). Skinfold thickness measurements were obtained from
the anterior abdominal wall, triceps, subscapular and suprailiac
skinfold regions using a skinfold calliper. Metabolic syndrome
was defined using International Diabetes Federation (IDF)
criteria, which include central obesity with a waist circumfer-
ence >−80 cm in females and >−94 cm in males, plus at least
2 of the following: systemic arterial hypertension, hyper-
triglyceridaemia, low levels of HDL-C, T2DM or raised fasting
glucose.23 MBI was calculated from weight (kg)/height (m)2.Biochemistry
Venous blood samples taken from an antecubital vein after an
overnight fast were assayed for serum glucose, insulin, ALT,
aspartate aminotransferase (AST), gammaglutamyl transpeptidase
(GGT), triglycerides, total cholesterol (TC), HDL-C, ferritin, trans-
ferrin saturation, high-sensitivity C-reactive protein (CRP),JHEP Reports 2020adiponectin and leptin. The HOMA-IR score was calculated as
[fasting insulin (lU/ml) × fasting glucose (mmol/L)]/22.5. LDL-C
was derived using the Friedewald equation.24 RLP-C levels were
calculated as total cholesterol – (HDL-C + LDL-C).18Statistical analysis
Sex-specific analyses were performed because of previously
identified sex differences in the prevalence of NAFLD and in as-
sociations between NAFLD and cardiometabolic covariates in the
Raine Study.5 Continuous descriptive data were summarised as
means and standard deviations, with categorical variables as
proportions. The main outcome variables were the ultrasound
diagnosis of NAFLD and severity of steatosis. Differences in
continuous variables between adolescents with or without
NAFLD were computed using the independent t test, analysis of
variance (ANOVA) or, for nonparametric variables, the Mann-
Whitney U test or Kruskal-Wallis test. Differences between cat-
egorical variables were determined with the Pearson Chi-square
test or Fisher’s exact test. Correlation coefficients were sought
using Pearson’s correlation. We had 95% power to detect a 24%
change in odds ratio, at a = 0.05 with a sample size of 1,170
subjects using multivariable logistic regression analysis3vol. 2 j 100150
Table 2. Correlations between RLP-C, anthropometric, cardiovascular and
biochemical variables in the whole cohort.
Variable Males Females
r p value r p value
Weight (kg) 0.24 <0.001 0.16 <0.001
Body mass index (kg/m2) 0.28 <0.001 0.20 <0.001
Waist (cm) 0.03 0.58 0.18 <0.001
SAT (mm) 0.25 <0.001 0.12 0.008
SST (mm) 0.26 <0.001 0.19 <0.001
VAT (mm) 0.11 0.03 0.11 0.03
SBP (mmHg) 0.17 <0.001 0.12 0.01
DBP (mmHg) 0.12 0.008 0.04 0.45
Pulse (bpm) 0.04 0.38 0.12 0.007
ALT (U/L) 0.16 <0.001 0.04 0.35
AST (U/L) 0.03 0.50 0.07 0.14
GGT (U/L) 0.22 <0.001 0.20 <0.001
TG (mmol/L) 0.99 <0.001 0.99 <0.001
Total cholesterol (mmol/L) 0.27 <0.001 0.32 <0.001
HDL-C (mmol/L) −0.27 <0.001 −0.20 <0.001
LDL-C (mmol/L) 0.003 0.94 0.11 0.02
Insulin (mU/L) 0.33 <0.001 0.30 <0.001
HOMA-IR 0.33 <0.001 0.29 <0.001
Glucose (mmol/L) 0.08 0.07 0.02 0.70
hsCRP (mg/L) −0.002 0.97 0.07 0.16
Leptin (lg/L) 0.26 <0.001 0.26 <0.001
Adiponectin (mg/L) −0.12 0.008 −0.18 <0.001
Data are presented as Pearson’s correlation coefficients (r). p values are for associa-
tions between RLP-C and other variables. p values <0.05 are considered statistically
significant.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood
pressure; GGT, gamma-glutamyl transpeptidase; HDL-C, high density lipoprotein
cholesterol; HOMA-IR, homeostasis model assessment for insulin resistance; hsCRP,
high sensitivity CRP; LDL-C, low density lipoprotein cholesterol; r, correlation coef-
ficient; RLP-C, remnant lipoprotein cholesterol; SAT, subcutaneous adipose thickness;















Fig. 1. Association between serum RLP-C levels and steatosis severity in














Fig. 2. Association between serum RLP-C levels and steatosis severity in
male subjects. RLP-C, remnant lipoprotein cholesterol.
Research article(G*Power 3.1). Multivariable logistic regression models were
used to calculate the odds of NAFLD from adolescent physical
assessment and biochemistry that were statistically significant in
univariate analysis, as well as HOMA-IR. All p values are reported
as two-sided, and p <0.05 was considered significant. Data were
analysed using IBM SPSS statistics for Windows (version 20.0;
IBM Corp., Armonk, NY, USA).Results
NAFLD
Liver ultrasound was performed on 1,170 adolescents (51% male),
of whom 1,162 had anthropometry, 1,165 cardiovascularJHEP Reports 2020assessment, 992 fasting blood tests and 1,122 arterial stiffness
measurements. Mean age was 17.0 (standard deviation 0.3)
years. Most adolescents (98% of males and 99% of females) were
pubertal or post-pubertal, according to the Tanner scale. The
Tanner stage of puberty was not associated with the presence or
absence of NAFLD (p >0.05). Among the adolescents, 21.4% had
central obesity (33.2% female versus 9.9% male, p <0.05) using
IDF waist circumference criteria. By contrast, using BMI criteria,
only 7.5% (8.0% female vs. 6.9% male, p = 0.48) were obese,
whereas 20.6% (22.1% female and 19.2% male, p = 0.21) were
overweight/obese. Median alcohol intake was 10 g per week
[interquartile range (IQR) 0–90 g per week] during the preceding
12 months. Three adolescents were excluded from the analysis
because of excessive alcohol intake. NAFLD was diagnosed in 177
(15.1%), comprising 19.6% females and 10.7% males (p <0.001).
Among the adolescents with NAFLD, 8.7% (12.7% female and 4.9%
male) had mild steatosis, whereas 6.1% (6.8% female and 5.4%
male) had moderate–severe steatosis. General and subcutaneous
adiposity indices, serum triglycerides, LDL-C, RLP-C, ALT, GGT,
leptin, insulin, HOMA-IR, hsCRP, C-AGPH-HR75 and Alx were
higher, whereas HDL-C and adiponectin were lower in those
with NAFLD compared with those without NAFLD (Table 1).
Remnant lipoprotein cholesterol
Fasting serum RLP-C levels were positively correlated with gen-
eral and subcutaneous adiposity, systolic blood pressure, serum
GGT, insulin, HOMA-IR, total cholesterol, LDL-C, triglycerides and
leptin, but negatively correlated with HDL-C and adiponectin.
RLP-C was not significantly associated with visceral adiposity,
serum ALT or AST (Table 2).
Relationship between NAFLD, obesity and serum RLP-C
NAFLDwasmore prevalent in obese adolescents than in nonobese
adolescents. Serum RLP-C levels were higher in adolescents with
NAFLD compared with those without NAFLD (Table 1). Increasing
serum RLP-C levels were associated with increasing severity of
hepatic steatosis [mean (SD) RLP-C 0.47 (0.24) mmol/L, 0.50
(0.23) mmol/L and 0.62 (0.31) mmol/L] for absent steatosis, mild
steatosis and moderate-severe steatosis, respectively (p <0.001)
(Figs 1 and 2).
Relationship between serum RLP-C and other serum
biochemical characteristics
Adolescents with RLP-C in the highest quartile had higher serum
GGT, leptin, total cholesterol, LDL-C, triglycerides, fasting insulin,4vol. 2 j 100150
Table 3. Comparison of lowest and highest RLP-C quartiles in adolescents with non-alcoholic fatty liver disease.
Variable Non-alcoholic fatty liver disease
Males Females
RLP-C Q1 (n = 33) RLP-C Q4 (n = 62) p value RLP-C Q1 (n = 204) RLP-C Q4 (n = 187) p value
Weight (kg) 81.5 (19.5) 104.6 (19.0) 0.002 67.7 (13.5) 76.0 (15.5) 0.046
BMI (kg/m2) 24.60 (4.75) 32.9 (5.1) <0.001 24.1 (4.5) 27.7 (5.8) 0.02
Waist (cm) 94.1 (17.9) 96.7 (15.8) 0.69 81.7 (11.4) 88.2 (14.2) 0.09
SAT (mm) 21.3 (12.4) 36.9 (11.1) 0.001 26.2 (12.7) 34.3 (14.8) 0.04
SST (mm) 20.4 (9.9) 32.8 (6.7) 0.001 24.2 (9.0) 25.9 (8.6) 0.51
VAT (mm) 35.1 (12.8) 47.9 (20.1) 0.10 31.8 (11.5) 36.3 (10.2) 0.22
SBP (mmHg) 110.85 (9.18) 129.3 (10.0) 0.001 107.0 (6.2) 112.0 (12.7) 0.10
DBP (mmHg) 57.7 (6.8) 62.3 (8.1) 0.11 58.9 (5.7) 59.4 (6.6) 0.75
Pulse (bpm) 64.0 (10.2) 70.1 (12.2) 0.11 63.7 (9.7) 70.3 (10.9) 0.02
ALT (U/L) 29.0 (12.1) 49.1 (27.7) 0.03 20.4 (20.7) 21.9 (11.6) 0.72
AST (U/L) 27.8 (5.9) 35.1 (19.9) 0.27 21.0 (7.2) 21.7 (5.2) 0.71
GGT (U/L) 15.2 (6.1) 29.6 (17.3) 0.01 11.1 (4.8) 16.9 (8.6) 0.003
TG (mmol/L) 0.6 (0.1) 1.8 (0.6) <0.001 0.6 (0.1) 1.7 (0.5) <0.001
Total cholesterol (mmol/L) 3.1 (0.7) 4.5 (0.7) <0.001 3.8 (0.8) 4.8 (0.9) <0.001
HDL-C (mmol/L) 1.2 (0.2) 1.0 (0.2) 0.02 1.4 (0.3) 1.2 (0.3) 0.01
LDL-C (mmol/L) 1.7 (0.6) 2.6 (0.8) 0.001 2.2 (0.6) 2.8 (0.8) 0.004
HOMA-IR 1.3 (0.8–2.6) 3.3 (2.2–5.4) 0.002 1.6 (1.2–2.4) 2.6 (1.6–3.7) 0.04
Glucose (mmol/L) 4.9 (0.3) 5.1 (0.5) 0.20 4.7 (0.4) 4.6 (0.4) 0.82
Insulin (mU/L) 6.1 (3.5–10.9) 14.0 (10.1–21.6) 0.003 7.7 (6.1–12.0) 12.5 (8.1–17.7) 0.02
hsCRP (mg/L) 0.8 (0.2–1.4) 1.6 (0.9–4.1) 0.007 0.4 (0.2–2.1) 1.6 (0.7–5.6) 0.02
Leptin (lg/L) 6.1 (3.2–18.0) 23.2 (11.7–39.3) 0.001 31.4 (24.4–45.7) 49.2 (35.3–67.3) 0.01
Adiponectin (mg/L) 8.2 (2.8) 6.1 (2.4) 0.03 12.5 (5.8) 7.8 (3.4) <0.001
Abdominal obesity (%) 40.0 52.0 0.78 42.9 73.5 0.04
Metabolic syndrome (%) 0.0 50.0 <0.001 0.0 26.5 <0.001
C-AGPH-HR75 −9.4 (10.5) −1.2 (10.8) 0.045 −8.0 (5.9) −6.1 (9.4) 0.42
Arterial augmentation index 97.5 (9.2) 104.6 (11.2) 0.08 99.8 (7.0) 98.4 (9.7) 0.59
Arterial pulse wave velocity 6.4 (0.6) 6.8 (0.9) 0.18 6.1 (0.7) 6.3 (0.6) 0.36
Data are presented as mean (standard deviation), median (interquartile range) or as proportions. Differences in continuous variables between adolescents in the lowest
quartile and top quartile of RLP-C were computed using the independent t test or the Mann-Whitney U test. Differences between categorical variables were determined with
the Pearson Chi-square test or Fisher's exact test. p values are for comparisons between Q1 and Q4 of RLP-C. p values <0.05 are considered statistically significant.
Metabolic syndrome is defined using International Diabetes Federation (IDF) criteria. Abdominal obesity was defined as waist circumference >−80 cm in females and >−94 cm in
males.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; C-AGPH-HR75, Central Augmentation Pressure/Pulse Height Ratio at Heart Rate 75; DBP, diastolic blood
pressure; GGT, gamma-glutamyl transpeptidase; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin resistance; hsCRP, high
sensitivity CRP; LDL-C, low density lipoprotein cholesterol; RLP-C, remnant lipoprotein cholesterol; SAT, subcutaneous adipose thickness; SBP, systolic blood pressure;
SST, suprailiac skinfold thickness; VAT, visceral adipose thickness.HOMA-IR and hsCRP compared with those in the lowest quartile
of RLP-C. Males, but not females, in the highest quartile of RLP-C
also had raised serum ALT (Table 3).
Relationship between serum RLP-C, anthropometric
characteristics and cardiovascular measures in adolescents
with NAFLD
Among adolescents with NAFLD, those in the highest quartile of
RLP-C had higher rates of central obesity, greater prevalence of
metabolic syndrome, as well as higher general and subcutaneous
adiposity. Males in the highest quartile of RLP-C also had higher
systolic blood pressure and C-AGPH-HR75 (Table 3).
Prediction of NAFLD
Using multivariable logistic regression analysis, serum RLP-C
levels in the lowest quartile were associated with reduced risk
of NAFLD (Table 4). In males, serum RLP-C levels in the lowest
quartile were associated with 85% reduced odds of being found
to have NAFLD, whereas higher waist circumference, serum ALT
and leptin were associated with a NAFLD diagnosis after
adjusting for serum adiponectin, HOMA-IR and hsCRP. By
contrast, in females, serum RLP-C levels in the lowest quartile
were associated with 55% reduced odds of being found to have
NAFLD, whereas higher waist circumference and serum leptin
and lower adiponectin were associated with NAFLD afterJHEP Reports 2020adjusting for HOMA-IR and serum hsCRP (Table 4). These
associations remained significant after adjusting for serum
triglycerides, HDL-C and LDL-C.Discussion
In this cohort study of well-characterised population-based ad-
olescents, there was a 15% prevalence of NAFLD. NAFLD was
associated with fasting serum RLP-C levels after adjusting for
traditional risk factors of adiposity and insulin resistance.
Furthermore, the severity of hepatic steatosis increased with
increasing serum RLP-C, providing a potential further link
between adolescent NAFLD and atherogenic dyslipidaemia,
metabolic syndrome, general and subcutaneous adiposity,
hyperleptinaemia and insulin resistance.
In adolescents with NAFLD, serum RLP-C levels were posi-
tively associated with serum ALT, GGT, hsCRP, and car-
diometabolic risk factors, including fasting insulin, HOMA-IR,
subcutaneous and visceral adiposity, systolic blood pressure,
pulse rate and measures of arterial stiffness. There was a sex-
related association between NAFLD and cardiometabolic risk
factors. Male adolescents with NAFLD or with the highest quar-
tile of RLP-C also had increased visceral adiposity, systolic blood
pressure and features of arterial stiffness. This might imply a
higher future risk of CVD in males compared with females with5vol. 2 j 100150
Table 4. Prediction models for non-alcoholic fatty liver disease.
Characteristics Multivariable analysis in males (OR, 95% CI) p value Multivariable analysis in females (OR, 95% CI) p value
Waist circumference (cm) 1.19 (1.13–1.25) <0.001 1.04 (1.01–1.07) <0.001
RLP-C (mmol/L)
Q1 0.15 (0.03–0.72) 0.12 0.44 (0.20–0.99) 0.18
Q2 0.49 (0.14–1.77) 0.02 0.61 (0.29–1.31) 0.048
Q3 0.36 (0.10–1.37) 0.28 0.86 (0.42–1.76) 0.21
Q4 Reference 0.14 Reference 0.69
ALT (U/L) 1.05 (1.01–1.08) 0.005
Leptin (lg/L) 1.14 (1.08–1.19) <0.001 1.02 (1.01–1.03) 0.007
Adiponectin (mg/L) 0.94 (0.888–0.996) 0.04
Data are presented as odds ratios and 95% confidence intervals (CIs). Multivariable logistic regression models were used to calculate the odds of NAFLD from adolescent
physical assessment and biochemistry that were statistically significant in univariate analysis, adjusted for homeostasis model assessment for insulin resistance (HOMA-IR),
adiponectin and high sensitivity CRP (hsCRP) in each sex. p values <0.05 are considered statistically significant.
ALT, alanine aminotransferase; OR, Odds ratio; Q1, lowest (first) quartile; Q2, second quartile; Q3, third quartile; Q4, top (fourth) quartile; RLP-C, remnant lipoprotein
cholesterol.
Research articleNAFLD, as previously described using the Framingham risk
score.25 Although waist circumference, serum RLP-C and leptin
levels were associated with NAFLD in both sexes, serum ALT was
also associated with NAFLD only in male adolescents, whereas
adiponectin was associated with NAFLD only in female
adolescents.
A recent study showed an association between higher circu-
lating RLP-C, severity of hepatic steatosis and prevalence of CVD
and cerebrovascular disease in adults with NAFLD.18 Further-
more, other studies reported an increasing prevalence and
burden of NAFLD in global populations, mirroring the increasing
rates of the metabolic syndrome.6,11 Several population studies,
systematic reviews and meta-analyses have identified CVD as the
leading cause of morbidity and mortality in adults with
NAFLD.26–29 Notably, NAFLD is associated with endothelial
dysfunction, increased carotid intima thickness, arterial stiffness
and left ventricular mass, and left ventricular diastolic dysfunc-
tion.30 By contrast, a population-based study using primary care
databases from three European countries recently reported no
significant increase in CVD related to fatty liver.31 However, the
case definition of NAFLD was not clearly stated, NAFLD preva-
lence was extraordinarily low, the duration of follow-up was
relatively short and the study population included adolescents
and young adults who would normally be expected to be at low
risk for cardiovascular outcomes. A possible role for RLP-C in
predicting risk of cardiovascular events in adults treated with
statins or with T2DM and chronic kidney disease has beenJHEP Reports 2020described in Japanese studies.32,33 Consequently, our findings
could contribute to the identification of adolescents at future risk
of CVD who could benefit from cardiometabolic risk reduction.
The strengths of our study include the large population size,
from a well-characterised cohort of adolescents with ultrasound
assessment of NAFLD and with detailed metabolic risk factor
assessment.5 A limitation of the study is the use of ultrasound,
rather than histology or MRI to diagnose NAFLD. However, ul-
trasound is the preferred initial non-invasive test for NAFLD
supported by the American Association for the Study of Liver
Disease and the European Association for the Study of the
Liver.2,34 In addition, liver biopsy in healthy, population-based
adolescents could not be justified.Conclusion
In conclusion, RLP-C was associated with NAFLD after adjusting
for adiposity and insulin resistance. Raised serum RLP-C levels
were associated with increased risk of the metabolic syndrome,
severity of hepatic steatosis and increased adiposity in adoles-
cents. However, those with NAFLD and lower RLP-C levels
appeared to have reduced severity of cardiometabolic risk fac-
tors. Consequently, the demonstration of an association between
RLP-C and cardiovascular risk in individuals with NAFLD could
aid in the identification of those who might benefit from tar-
geted risk factor assessment and management before the
development of adverse cardiovascular outcomes.Abbreviations
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